Browse

OHRP has experienced an unprecedented exodus of ethics expertise, raising concerns about its ability to effectively protect volunteers.

Americans who have high-risk exposures to Ebola in the current outbreak in Central Africa will have access to an experimental antibody treatment.

Otsuka Pharmaceutical reported new evidence on Thursday that it thinks will help support a full approval for its monoclonal antibody Voyxact in a chronic autoimmune disease that affects the kidneys…